ADAPTIVE BIOTECHNOLOGIES CORPORATION Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -7.20% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- ADAPTIVE BIOTECHNOLOGIES CORPORATION effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -7.20%.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -4.80%.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -2.90%.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -2.00%, a 114.18% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -7.20% 10-K · filed 2026-02-26 | |
| 2024-12-31 | -4.80% 10-K · filed 2026-02-26 | -4.70% 10-K · filed 2025-03-03 |
| 2023-12-31 | -2.90% 10-K · filed 2026-02-26 | |
| 2022-12-31 | -2.00% 10-K · filed 2025-03-03 | |
| 2021-12-31 | 14.10% 10-K · filed 2024-02-29 | |
| 2020-12-31 | 25.20% 10-K · filed 2023-02-14 | |
| 2019-12-31 | 9.80% 10-K · filed 2022-02-15 | |
| 2018-12-31 | 0.50% 10-K · filed 2021-02-24 | |
| 2017-12-31 | -1.70% 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |